Адренорецепторы: подтипы α

α1 receptors are located postsynaptically on effector organs and activate phospholipase C, releasing IP3 and DAG as secondary messengers, causing vasoconstriction and increased blood pressure. α2 receptors are predominantly presynaptic on nerve terminals and pancreatic beta cells, inhibiting adenylyl cyclase to decrease cAMP production, modulating neurotransmitter release and insulin secretion.

α1 receptor stimulation activates the phospholipase C pathway, releasing IP3 and DAG as secondary messengers. In cardiovascular smooth muscle, this causes vasoconstriction and increased blood pressure. In GI smooth muscle, α1 activation leads to muscle relaxation, reducing GI motility and contractions.

α2 receptors are predominantly located on autonomic nerve terminals, pancreatic beta cells, vascular smooth muscles, and platelets. Upon stimulation, they inhibit adenylyl cyclase and decrease cAMP production, modulating the release of autonomic neurotransmitters and insulin, controlling vascular smooth muscle contraction, and affecting platelet aggregation.

Tamsulosin preferentially inhibits α1-A receptors in the prostate gland over α1-B receptors in blood vessels. This receptor subtype selectivity allows the drug to treat prostatic hyperplasia effectively while minimizing cardiovascular effects like hypotension that occur when α1-B receptors in blood vessels are blocked.

Both α1 and α2 receptors show higher affinity for adrenaline and noradrenaline than isoprenaline. However, α1 receptors are classified based on their postsynaptic location and phospholipase C activation, while α2 receptors are classified by their presynaptic location and adenylyl cyclase inhibition, reflecting distinct functional roles in the autonomic nervous system.

α1 receptors are subdivided into α1-A, α1-B, and α1-D subtypes, while α2 receptors are subdivided into α2-A, α2-B, and α2-C subtypes. These subdivisions are based on subtype-selective drugs and their differential tissue distribution, allowing for more precise pharmacological targeting and understanding of drug-receptor selectivity.

α2 receptor activation inhibits adenylyl cyclase, decreasing intracellular cAMP production and causing closure of ion channels. This mechanism contrasts with α1 receptors, which activate phospholipase C. The reduced cAMP and ion channel closure modulate autonomic neurotransmitter release and regulate vascular smooth muscle and platelet function.